On July 28, GSK plc (NYSE:GSK) reported its second-quarter financial results, delivering strong core operational performance and showcasing steady commercial momentum. The firm’s total Q2 turnover reached £8.4 billion, marking a 5% increase year-over-year at constant exchange rates (CER), while Core operating profit climbed 7% CER to £2.80 billion and Core EPS rose 9% CER to 50.5p. Growth was primarily fueled by double-digit gains in Specialty Medicines (+14% CER to £3.8 billion) and robust momentum in Vaccines (+8% CER to £2.3 billion). However, Total operating profit dropped 75% CER to £481 million, hit by a £1.3 billion non-cash impairment charge following the decision to discontinue camlipixant after CALM-1/2 Phase III trial results.
Alongside earnings, GSK outlined major strategic plans to accelerate its R&D roadmap. Management announced it expects 20+ Phase III trial starts in 2026, up from its previous projection of 10, focusing on 7 key asset accelerations across 18 indications in oncology, respiratory, hepatology, and vaccines.
To support this pipeline expansion and fund late-stage development, GSK initiated its new ‘Accelerate Growth’ restructuring program. The three-year initiative aims to generate £1.9 billion in annual cost savings by 2029 for total costs of £2.4 billion, with savings earmarked for pipeline reinvestment and supporting operating margins through the dolutegravir loss-of-exclusivity period (2028–2030). Additionally, ViiV Healthcare, GSK’s majority-owned HIV business, presented positive Phase IIIb VOGUE study data, reinforcing the efficacy and real-world utility of its long-acting HIV regimen portfolio.
This brings up a key question: Is GSK plc (NYSE:GSK)’s pipeline acceleration and core business growth enough to offset upcoming patent expiries, or does statutory margin volatility signal deeper pipeline execution risks ahead?
Bull Case
Bullish analysts highlight that GSK plc’s core business model continues to show high execution efficiency, supported by key product launches and pipeline catalysts over the next 12 months that build confidence in reaching its £40 billion sales target by 2031. A critical driver is GSK plc’s active business development strategy, illustrated by the acquisition of efimosfermin, which expands its hepatology portfolio, provides optionality for related liver diseases, and seamlessly aligns with corporate M&A goals.
Furthermore, product development milestones provide immediate commercial inflection points. The upcoming launch of depemokimab presents a major growth opportunity as biologics continue to penetrate the severe respiratory market. Similarly, Blenrep’s U.S. PDUFA decision and commercial rollout are anticipated to be pivotal factors in driving oncology revenues toward long-term targets. With over 62 assets in clinical development and a newly announced flagship R&D center on the Cambridge Biomedical Campus, supporters argue GSK is aggressively securing its post-2031 growth outlook.
Bear Case
Bears point to significant external and execution headwinds that could cap medium-term equity upside. While management remains confident in navigating an uncertain macroeconomic and regulatory climate, structural revenue concentrations linger. Notably, GSK acknowledges that the majority (over 50%) of its £40 billion sales target by 2031 relies on products already on the market, leaving the company vulnerable to competitive pressure and pricing erosion before new late-stage pipeline assets fully mature.
The Q2 earnings report underscored these vulnerabilities: General Medicines revenue fell 9% CER to £2.3 billion due to Trelegy declines, while the £1.3 billion impairment on camlipixant served as a stark reminder of late-stage clinical trial risks. Furthermore, short-term margin compression from the £2.4 billion ‘Accelerate Growth’ restructuring charges, combined with the impending loss of exclusivity for key HIV compound dolutegravir between 2028 and 2030, means GSK must execute flawlessly across its 20+ Phase III trial launches to prevent revenue drag.
Insider Monkey’s Hedge Fund Data Analysis
Institutional positioning tracked by Insider Monkey shows a shift in smart money sentiment during the first half of the year. The number of hedge funds holding positions in GSK plc stood at 31 funds in Q1 2026, down from 43 funds in Q4 2025. Among notable holders, P.A.W. Capital Partners (managed by Peter A. Wright) held 5,050 shares valued at approximately $264,721, representing 0.2% of its 13F portfolio.
What Investors Should Watch Next
Investors should closely monitor GSK plc (NYSE:GSK)’s upcoming Phase III trial progress, particularly for key pipeline assets such as depemokimab and bepirovirsen, along with regulatory milestones for Blenrep and newly acquired oncology therapies. Additionally, the execution of the company’s “Accelerate Growth” cost-saving program will be critical, as investors assess whether GSK can achieve its £1.9 billion annual savings target while maintaining commercial momentum and pipeline development.
While we acknowledge the risk and potential of GSK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GSK and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center